Sanofi (France) CEO Says He Kept The Genzyme Corporation Execs He Wanted

Sanofi, France’s biggest drugmaker, said it managed to retain key Genzyme Corp. (GENZ) executives following the acquisition of the U.S. biotechnology company. “The level of employee turnover has not changed significantly following the acquisition,” Sanofi Chief Executive Officer Chris Viehbacher told reporters on a call today. Sanofi completed the acquisition of Cambridge, Massachusetts-based Genzyme, the largest maker of medicines for rare genetic disorders, for at least $20.1 billion in April to gain innovative drugs that are less vulnerable to generic competition. Viehbacher said today Sanofi has “pretty much reached the conclusion of the integration phase.”

Back to news